NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis → Your 'AI Income Playbook' Awaits... (From The Oxford Club) (Ad) Free SBFM Stock Alerts $0.34 -0.06 (-14.10%) (As of 02:39 PM ET) Add Compare Share Share Today's Range$0.31▼$0.3850-Day Range$0.29▼$10.2052-Week Range$0.28▼$64.50Volume3.17 million shsAverage Volume2.19 million shsMarket Capitalization$6.39 millionP/E RatioN/ADividend YieldN/APrice Target$260.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Sunshine Biopharma alerts: Email Address Sunshine Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76,937.0% Upside$260.00 Price TargetShort InterestHealthy0.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSunshine Biopharma has received no research coverage in the past 90 days.Read more about Sunshine Biopharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.87% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 10.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SBFM. Previous Next 2.2 News and Social Media Coverage News SentimentSunshine Biopharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sunshine Biopharma this week, compared to 0 articles on an average week.Search InterestOnly 23 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders14.70% of the stock of Sunshine Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sunshine Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sunshine Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe Key to this $10 Trillion Tech BoomPresident Biden has just approved $2.6 billion for this breakthrough technology… And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. About Sunshine Biopharma Stock (NASDAQ:SBFM)Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.Read More SBFM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SBFM Stock News HeadlinesJune 12 at 2:50 AM | americanbankingnews.comSunshine Biopharma (NASDAQ:SBFM) Trading Down 10.6%May 21, 2024 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%May 21, 2024 | finance.yahoo.comSunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%May 20, 2024 | msn.comSBFM Stock Earnings: Sunshine Biopharma Beats EPS, Beats Revenue for Q1 2024May 16, 2024 | investorplace.com3 Meme Stocks to Sell That Even Roaring Kitty Can't SaveApril 22, 2024 | msn.comSBFM, BPTH and INDO among pre-market losersApril 19, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.56%April 19, 2024 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg, a Biosimilar of NeulastaApril 12, 2024 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma Announces Reverse Stock SplitApril 8, 2024 | investorplace.comSBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q4 2023April 4, 2024 | seekingalpha.comSBFM Sunshine Biopharma, Inc.March 6, 2024 | cnn.comSunshine Biopharma IncorporatedMarch 4, 2024 | investorplace.comWhy Is Sunshine Biopharma (SBFM) Stock Down 17% Today?February 15, 2024 | finance.yahoo.comSunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public OfferingJanuary 23, 2024 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From Sunshine Biopharma, Inc. (NASDAQ:SBFM)November 28, 2023 | benzinga.comSunshine Biopharma Stock (NASDAQ:SBFM) Dividends: History, Yield and DatesSeptember 22, 2023 | finanznachrichten.deSunshine Biopharma, Inc.: Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid ComplianceSeptember 22, 2023 | finance.yahoo.comSunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid ComplianceSeptember 14, 2023 | investopedia.comWhat Are Sunshine Laws? Definition, Purpose, ExamplesSeptember 12, 2023 | finance.yahoo.comIt's Down 26% But Sunshine Biopharma, Inc. (NASDAQ:SBFM) Could Be Riskier Than It LooksAugust 16, 2023 | finance.yahoo.comWhen Will Sunshine Biopharma, Inc. (NASDAQ:SBFM) Breakeven?August 11, 2023 | finanznachrichten.deSunshine Biopharma Inc.: Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%August 11, 2023 | finance.yahoo.comSunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%May 16, 2023 | finanznachrichten.deAegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc.May 16, 2023 | finance.yahoo.comSunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketSee More Headlines Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today6/14/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SBFM CUSIPN/A CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$260.00 High Stock Price Target$260.00 Low Stock Price Target$260.00 Potential Upside/Downside+66,074.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($13.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,510,000.00 Net Margins-15.29% Pretax Margin-13.90% Return on Equity-17.95% Return on Assets-14.18% Debt Debt-to-Equity RatioN/A Current Ratio4.41 Quick Ratio3.23 Sales & Book Value Annual Sales$24.09 million Price / Sales0.31 Cash FlowN/A Price / Cash FlowN/A Book Value$82.58 per share Price / Book0.00Miscellaneous Outstanding Shares18,940,000Free Float16,160,000Market Cap$7.44 million OptionableNot Optionable Beta1.51 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Steve N. Slilaty Ph.D. (Age 72)CEO, President & Chairman Comp: $640kMr. Camille Sebaaly (Age 65)CFO & Secretary Comp: $695kDr. Abderrazzak Merzouki (Age 60)Chief Science Officer & Director Comp: $340kMr. Marc Beaudoin (Age 57)Chief Operating Officer Mr. Malek Chamoun (Age 39)Chief Development Officer Mr. Robert G. Ferreira (Age 62)President of Sunshine Bio Investments Inc More ExecutivesKey CompetitorsLexaria BioscienceNASDAQ:LEXXEyenoviaNASDAQ:EYENImmuneeringNASDAQ:IMRXLipocineNASDAQ:LPCNReviva PharmaceuticalsNASDAQ:RVPHView All CompetitorsInsidersSteve N SlilatyBought 1,000 shares on 3/4/2024Total: $10,000.00 ($10.00/share)View All Insider Transactions SBFM Stock Analysis - Frequently Asked Questions Should I buy or sell Sunshine Biopharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sunshine Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SBFM shares. View SBFM analyst ratings or view top-rated stocks. What is Sunshine Biopharma's stock price target for 2024? 1 brokerages have issued 1 year price objectives for Sunshine Biopharma's stock. Their SBFM share price targets range from $260.00 to $260.00. On average, they expect the company's stock price to reach $260.00 in the next year. This suggests a possible upside of 76,937.0% from the stock's current price. View analysts price targets for SBFM or view top-rated stocks among Wall Street analysts. How have SBFM shares performed in 2024? Sunshine Biopharma's stock was trading at $27.15 on January 1st, 2024. Since then, SBFM stock has decreased by 98.8% and is now trading at $0.3375. View the best growth stocks for 2024 here. When is Sunshine Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our SBFM earnings forecast. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) released its quarterly earnings results on Monday, May, 20th. The company reported ($2.00) EPS for the quarter. The firm had revenue of $7.54 million for the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 17.95% and a negative net margin of 15.29%. When did Sunshine Biopharma's stock split? Sunshine Biopharma shares reverse split on Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SBFM) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.